Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailL'ostéoporose
Reginster, Jean-Yves ULg

in Medipractice Digest (1993)

Detailed reference viewed: 11 (2 ULg)
See detailL'ostéoporose: une maladie qui s'évite
Bruyère, Olivier ULg

Conference (2000, March 18)

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailOsteoporosis
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Cianferotti, Luisella et al

Book published by Future Medicine Ltd (2013)

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : the interest of a prospective vision
Gillet, Pierre ULg; Reginster-Haneuse, G; Reginster, Jean-Yves ULg

in Osteoporosis International (1996), 6(S1), 119

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : The interest of a prospective vision
Gillet, Pierre ULg; Gosset, Christiane ULg; Reginster, Jean-Yves ULg

in Calcified Tissue International (1997), 61

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Breart, G.; Cooper, C.; Meyer, O. et al

in Osteoporosis International (2010), 21

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female ... [more ▼]

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients. INTRODUCTION: We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment. METHODS: A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N = 11,546), osteoporotic women treated with alendronate (N = 20,084), or strontium ranelate (N = 2,408), and a sample of non-osteoporotic women (N = 115,009). Cohorts were compared using a Cox proportional hazards regression model. RESULTS: There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient-years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09-1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient-years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60-2.01) for strontium ranelate and 0.92 (95% CI, 0.63-1.33) for alendronate. CONCLUSION: This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients. [less ▲]

Detailed reference viewed: 51 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in daily clinical practice: prevalence of acute predictors in French postmenopausal women
Tancredi, Annalisa ULg; Bosio-Le goux, B.; Augendre-Ferrante, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 108-109

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Endocrine (in press)

Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of ... [more ▼]

Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, crosssectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses is associated with decreased bone mineral density and increased fracture risk. The association between SSRIs use and fracture risk could potentially differ depending on dose, exposure duration, time of exposure, age, or sex. However, the risk of fracture declined rapidly after discontinuation of use of SSRIs. The evidence now seems sufficient to consider adding SSRIs to the list of medications that contribute to osteoporosis. In practice, assessment of risk factor for osteoporosis or fractures could be made taking into account age, gender, duration, and severity of depression, length of SSRI treatments, and other concurrent risk factors. [less ▲]

Detailed reference viewed: 16 (10 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in the European Union : a compendium of country-specific reports
Svedbom, A; Hernlund, E; Ivergard, M et al

in Archives of Osteoporosis (2013), 8(137), 1-218

This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27). INTRODUCTION: In 2010, 22 million women and 5.5 million men were ... [more ▼]

This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27). INTRODUCTION: In 2010, 22 million women and 5.5 million men were estimated to have osteoporosis in the EU; and 3.5 million new fragility fractures were sustained, comprising 620,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures. The economic burden of incident and prior fragility fractures was estimated at euro 37 billion. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining. The aim of this report was to characterize the burden of osteoporosis in each of the EU27 countries in 2010 and beyond. METHODS: The data on fracture incidence and costs of fractures in the EU27 were taken from a concurrent publication in this journal (Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden) and country specific information extracted. RESULTS: The clinical and economic burden of osteoporotic fractures in 2010 is given for each of the 27 countries of the EU. The costs are expected to increase on average by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining. CONCLUSIONS: In spite of the high cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by aging populations, the use of pharmacological prevention of osteoporosis has decreased in recent years, suggesting that a change in healthcare policy concerning the disease is warranted. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in the very elderly
Halkin, V; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Medicographia (2002), 24(4), 316-321

Detailed reference viewed: 11 (4 ULg)
Full Text
See detailOsteoporosis patients demonstrate high levels of vitamin D depletion
Bruyère, Olivier ULg

E-print/Working paper (2008)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis prevalence estimates for men: variation based on normative data
Gourlay, Margaret L; Richy, Florent; Garrett, Joanne et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 298

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis prevalence in men varies by the normative reference
Richy, F.; Gourlay, M. L.; Garrett, J. et al

in Journal of Clinical Densitometry (2004), 7

Controversy surrounds which normative data should be used to estimate osteoporosis prevalence in men. Prevalence estimates may vary significantly when different normative standards are applied. Five ... [more ▼]

Controversy surrounds which normative data should be used to estimate osteoporosis prevalence in men. Prevalence estimates may vary significantly when different normative standards are applied. Five normative datasets (NHANES female norms, local female norms, Hologic densitometer manufacturer female norms, NHANES male norms, Hologic male norms) were used to estimate the prevalence of osteoporosis by World Health Organization diagnostic criteria in a study population of 311 consecutive men between the age of 30 and 91 (mean 60.3 yr) referred to an outpatient osteoporosis center between January 1996 and December 1998. Statistically significant variations were seen in osteoporosis prevalence measured at three anatomical sites. The greatest relative variation was seen for the total femur, where osteoporosis prevalence ranged from 7.0% (NHANES and Hologic female norms) to 15.6% (NHANES male norms). The least relative variation was seen at the lumbar spine, where prevalence ranged from 18.1% (Hologic female norms) to 29.6% (local female norms). When considering osteoporosis at any site, prevalence was lowest (23.5%) based on Hologic female norms and highest (35.8%) based on local female norms. Interpretation of prevalence data should include an assessment of how normative standards influence reporting of the population at high risk of fracture. [less ▲]

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis: a still increasing prevalence
Reginster, Jean-Yves ULg

in Osteoporosis International (2005, March), 16(Suppl.3), 119

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis: A still increasing prevalence
Reginster, Jean-Yves ULg; Burlet, N.

in BONE (2006), 38(2 Suppl 1), 4-9

It is estimated that over 200 million people worldwide have osteoporosis. The prevalence of osteoporosis is continuing to escalate with the increasingly elderly population. The major complication of ... [more ▼]

It is estimated that over 200 million people worldwide have osteoporosis. The prevalence of osteoporosis is continuing to escalate with the increasingly elderly population. The major complication of osteoporosis is an increase in fragility fractures leading to morbidity, mortality, and decreased quality of life. In the European Union, in 2000, the number of osteoporotic fractures was estimated at 3.79 million. A baseline fracture is a very strong predictor of further fractures with 20% of patients experiencing a second fracture within the first year. The costs to health care services are already considerable and, on Current trends, are predicted to double by 2050. The direct costs of osteoporotic fractures to the health services in the European Union in the year 2000 were estimated at Euro32 billion. Guidelines for the diagnosis and treatment of osteoporosis are available in many countries; however, implementation is generally poor despite the availability of treatments with proven efficacy. Programs to increase awareness of osteoporosis and its outcomes are necessary for healthcare specialists and the general public. Earlier diagnosis and intervention prior to the first fracture are highly desirable. (c) 2005 Elsevier Inc. All rights reserved. [less ▲]

Detailed reference viewed: 36 (4 ULg)
Full Text
Peer Reviewed
See detailL'osteoradionecrose mandibulaire: epee de damocles de la radiotherapie cervico-faciale?
Piret, Pascal ULg; Deneufbourg, Jean-Marie ULg

in Revue Médicale de Liège (2002), 57(6), 393-9

RÉSUMÉ : Dotée d’une réelle efficacité, la radiothérapie des cancers cervico-faciaux peut toutefois être à l’origine de complications sévères. Heureusement peu fréquente, l’ostéoradionécrose mandibulaire ... [more ▼]

RÉSUMÉ : Dotée d’une réelle efficacité, la radiothérapie des cancers cervico-faciaux peut toutefois être à l’origine de complications sévères. Heureusement peu fréquente, l’ostéoradionécrose mandibulaire en constitue une des plus redoutables. Sa pathogénie relève d’altérations radiques au niveau de la muqueuse, de l’os et des glandes salivaires. Les facteurs de risque tiennent au patient, à la tumeur ainsi qu’aux modalités thérapeutiques. Une cascade d’événements prenant son origine dans l’hyposialie conduit à la nécrose osseuse via le développement de caries extensives et le traumatisme lié à l’extraction dentaire. Une prévention efficace existe, fondée sur une mise en ordre buccale préalablement à l’irradiation, sur des mesures hygiéno-diététiques et la pratique stricte de la fluoruration. Certains traitements médicaux peuvent stabiliser le processus. L’oxygénothérapie hyperbare exerce un effet bénéfique incontestable. Dans les cas les plus graves, une chirurgie reconstructrice par lambeau osseux libre microvascularisé constitue l’ultime recours pour restaurer tant la fonction que l’aspect cosmétique. Rapportant un cas clinique, l’importance de la bonne observance par le patient des principes de prévention est souligné. Parallèlement, l’accent est mis sur la nécessité d’une surveillance régulière exercée par le radiothérapeute afin d’éviter les conséquences gravissimes qui peuvent être celles de l’ostéoradionécrose mandibulaire. [less ▲]

Detailed reference viewed: 124 (4 ULg)
Full Text
Peer Reviewed
See detailL'ostéosarcome pagétique: prévention, diagnostic, attitude et pronostic
Reginster, Jean-Yves ULg; Franchimont, P

in Revue Médicale de Liège (1985), 40

Detailed reference viewed: 6 (1 ULg)
Full Text
See detailOstéroporose, le mal sournois
Reginster, Jean-Yves ULg

in Athena (2011), 276

Detailed reference viewed: 29 (1 ULg)